Form 4: Alto Neuroscience Director Acquires Stock Options in Lieu of Retainer Fees
SEC Form 4 Filing
Alto Neuroscience director, Gwill York, acquired 19,558 stock options in lieu of $62,000 in retainer fees.
Summary
- Gwill York, a director at Alto Neuroscience, acquired 19,558 stock options on January 2, 2025.
- These options were granted in lieu of $62,000 in retainer fees, as part of the company's Non-Employee Director Compensation Policy.
- The options have an exercise price of $4.38 per share and will vest in four equal installments throughout 2025, contingent on continued service.
- The first vesting date is March 31, 2025, with subsequent vestings on June 30, September 30, and December 31, 2025.
- The options expire on January 1, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, which is generally positive for aligning director and shareholder interests. The sentiment is neutral to slightly positive.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
- Using stock options instead of cash for retainer fees conserves company cash.
Risks
- The value of the stock options is dependent on the future performance of Alto Neuroscience's stock price.
- The director must remain in service through each vesting date to receive the options.
Industry Context
This type of compensation is common for non-employee directors in publicly traded companies, aligning their interests with shareholders and conserving cash.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for non-employee directors in the biotechnology industry.
- The vesting schedule of the options is typical, with vesting occurring over a period of time to incentivize continued service.
- The exercise price of $4.38 per share is a key factor in determining the value of the options, and will be compared to the market price of the stock at the time of vesting.
Stakeholder Impact
- Shareholders may view this as a positive move, aligning director interests with company performance.
- The company conserves cash by using stock options instead of cash for retainer fees.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the stock option grant. |
| 03/31/2025 | First vesting date for 4,889 shares. |
| 06/30/2025 | Second vesting date for 4,890 shares. |
| 09/30/2025 | Third vesting date for 4,889 shares. |
| 12/31/2025 | Fourth vesting date for 4,890 shares. |
| 01/01/2035 | Expiration date of the stock options. |
| 01/06/2025 | Date of the filing. |
Keywords
stock options, director compensation, insider trading, Alto Neuroscience, ANRO, equity, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.